Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · Fondazione IRCCS Istituto Nazionale dei Tumori · +30 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
521
total citations
- FWCI
- 28.37
- Percentile
- 100%
- References
- 12
Citations per year
Authors
27- PAPaolo A. AsciertoCorresponding
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
- MDMichele Del Vecchio
Fondazione IRCCS Istituto Nazionale dei Tumori
- MMMario Mandalà
Ospedale Papa Giovanni XXIII
- HGHelen Gogas
National and Kapodistrian University of Athens
- AAAna Arance
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Clínic de Barcelona
Topics & keywords
Topics
Keywords
- Ipilimumab
- Medicine
- Nivolumab
- Clinical endpoint
- Internal medicine
- Population
- Clinical trial
- Adjuvant
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.